Malignant pheochromocytomas and paragangliomas: A phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG)

Annals of the New York Academy of Sciences

Volumn 1073, Issue , 2006, Pages 465-490

  Fitzgerald, Paul A ^a,b,c   Goldsby, Robert E ^a,c   Huberty, John P ^b   Price, David C ^b   Hawkins, Randall A ^b   Veatch, Janet J ^a   Dela Cruz, Filemon ^a   Jahan, Thierry M ^a,c   Linker, Charles A ^a,c   Damon, Lloyd ^a,c   Matthay, Katherine K ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Malignant; MIBG; Paraganglioma; Pheochromocytoma

Indexed keywords

(3 IODOBENZYL)GUANIDINE; (3 IODOBENZYL)GUANIDINE I 131; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CALCIUM CHANNEL BLOCKING AGENT; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ENOXAPARIN; GRANISETRON; LEVOFLOXACIN; LORAZEPAM; MAGNESIUM SULFATE; MEDROXYPROGESTERONE ACETATE; METIROSINE; METOPROLOL; NICARDIPINE; NIFEDIPINE; ONDANSETRON; PHENOXYBENZAMINE; TUMOR MARKER; VANDETANIB; VASCULOTROPIN INHIBITOR; VINCRISTINE; ZOLEDRONIC ACID;

ADOLESCENT; ADOPTIVE IMMUNOTHERAPY; ADRENALECTOMY; ADULT; BONE MARROW SUPPRESSION; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CATALYSIS; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYOPRESERVATION; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG INFUSION; DRUG MEGADOSE; DRUG UPTAKE; ERYTHROCYTE; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; GRAVES DISEASE; HAIR DISEASE; HISTOPATHOLOGY; HOSPITAL CARE; HUMAN; HYPERTENSION; KAPLAN MEIER METHOD; LEUKAPHERESIS; MALE; METASTASIS; MULTIMODALITY CANCER THERAPY; MYELODYSPLASIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY INSUFFICIENCY; PARAGANGLIOMA; PATIENT CARE; PERIPHERAL BLOOD STEM CELL; PHASE 2 CLINICAL TRIAL; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RELAPSE; SCHOOL CHILD; SURVIVAL RATE; TESTIS DISEASE; THROMBOCYTE TRANSFUSION; TREATMENT RESPONSE;

EID: 33845510964     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1353.050     Document Type: Conference Paper

References (74)

1. BEARD, C.M. et al. 1983. Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clin. Proc. 58: 802-804.
2. STENSTROM, G. & K. SVARDSUDD. 1986. Pheochromocytoma in Sweden 1958-1981. An analysis of the National Cancer Registry Data. Acta Med. Scand. 220: 225-232.
3. HARTLEY, L. & D. PERRY-KEENE. 1985. Phaeochromocytoma in Queensland: 1970-83. Aust. N. Z. J. Surg. 55: 471-475.
4. ANDERSEN, G.S. et al. 1988. The incidence rate of phaeochromocytoma and Conn's syndrome in Denmark, 1977-1981. J. Hum. Hypertens. 2: 187-189.
5. BAGUET, J.P. et al. 2004. Circumstances of discovery of phaeochromocytoma: a retrospective study of 41 consecutive patients. Eur. J. Endocrinol. 150: 681-686.
6. SUTTON, M.G. et al. 1981. Prevalence of clinically unsuspected pheochromocytoma: review of a 50-year autopsy series. Mayo Clin. Proc. 56: 354-360.
7. CIFTCI, A.O. et al. 2001. Pheochromocytoma in children. J. Pediatr. Surg. 36: 447-452.
8. TANAKA, S. et al. 1993. Malignant pheochromocytoma with hepatic metastasis diagnosed 20 years after resection of the primary adrenal lesion. Intern. Med. 32: 789-794.
9. LEHNERT, H. et al. 2004. Malignant pheochromocytoma. In Pheochromocytoma. Pathophysiology and Clinical Management. Frontiers of Hormone Research. Vol. 31, A.B. Grossman, Ed.: 155-162. S. Karger. Basel, Switzerland.
10. THOMPSON, L.D.R. 2002. Pheochromocytoma of the adrenal gland scaled score (PASS) to separate benign from malignant neoplasms. Am. J. Surg. Pathol. 26: 551-556.
11. KIMURA, N. et al. 2005. Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors. Endocr. Pathol. 16: 23-32.
12. BROWN, H.M. et al. 1999. Predicting metastasis of pheochromocytomas using DNA flow cytometry and immunohistochemical markers of cell proliferation. Cancer 86: 1583-1589.
13. SALMENKIVI, K. et al. 2001. Increased expression of cyclooxygenase-2 in malignant pheochromocytomas. J. Clin. Endocrinol. Metab. 86: 5615-5619.
14. OISHI, S. & T. SATO. 1988. Elevated serum neuron-specific enolase in patients with malignant pheochromocytoma. Cancer 61: 1167-1170.
15. RAO, F. et al. 2000. Malignant pheochromocytoma: chromaffin granule transmitters and response to treatment. Hypertension 36: 1045-1052.
16. SHORT, J.H. & T.D. DARBY. 1967. Sympathetic nervous system blocking agents. III. Derivatives of benzylguanidine. J. Med. Chem. 10: 833-840.
17. SISSON, J.C. et al. 1981. Scintigraphic localization of pheochromocytoma. N. Engl. J. Med. 305: 12-17.
18. SHAPIRO, B. et al. 1984. The location of middle mediastinal pheochromocytomas. J. Thoracic Cardiovasc. Surg. 87: 814-820.
19. SHAPIRO, B. et al. 1985. Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases. J. Nucl. Med. 26: 576-585.
20. HATTNER, R.S. et al. 1984. Scintigraphic detection of pheochromocytomas using m-iodo (I-131) benzylguanidine. Noninvasive Med. Imaging 1: 105-109.
21. TSUCHIMOCHI, S. et al. 1997. Metastatic pulmonary pheochromocytomas: positive I-123 MIBG imaging with negative I-131 MIBG and equivocal I-123 MIBG planar imaging. Clin. Nucl. Med. 22: 687-690.
22. ARGIRIS, A. et al. 2003. PET scan assessment of chemotherapy response in metastatic paraganglioma. Am. J. Clin. Oncol. 26: 563-566.
23. PACAK, K. et al. 2004. Functional imaging of endocrine tumors: role of positron emission tomography. Endocr. Rev. 25: 569-580.
24. MUKHERJEE, J.J. et al. 1997. Pheochromocytoma: effect of nonionic contrast medium in CT on circulating catecholamine levels. Radiology 202: 227-231.
25. ILIAS, I. & K. PACAK. 2004. Anatomical and functional imaging of metastatic pheochromocytoma. Ann. N.Y. Acad. Sci. 1018: 495-504.
26. KHORRAM-MANESH, A. et al. 2004. Mortality associated with pheochromocytoma in a large Swedish cohort. Eur. J. Surg. Oncol. 30: 556-559.
27. BRAVO, E.L. 2002. Pheochromocytoma: an approach to antihypertensive management. Ann. N. Y. Acad. Sci. 970: 1-10.
28. SANTEIRO, M.L. et al. 1996. Phenoxybenzamine placental transfer during the third trimester. Ann. Pharmacother. 30: 1249-1251.
29. COMBEMALE, F. et al. 1998. Exclusive use of calcium channel blockers and cardioselective beta-blockers in the pre- and peri-operative management of pheochromocytomas. 70 cases. Ann. Chir. 52: 341-345.
30. LEBUFFE, G. et al. 2005. The effect of calcium channel blockers on outcome following the surgical treatment of phaeochromocytomas and paragangliomas. Anaesthesia 60: 439-444.
31. 131I-meta-iodobenzylguanidine kinetics in malignant phaeochromocytoma. Eur. J. Nucl. Med. 14: 345-348.
32. MINAMI, T. et al. 2002. An effective use of magnesium sulfate for intraoperative management of laparoscopic adrenalectomy for pheochromocytoma in a pediatric patient. Anesth. Analg. 95: 1243-1244.
33. KHAFAGI, F.A. et al. 1989. Labetalol reduces iodine-131 MIBG uptake by pheochromocytoma and normal tissues. J. Nucl. Med. 30: 481-489.
34. STEINSAPIR, J. et al. 1997. Metyrosine and pheochromocytoma. Arch. Intern. Med. 157: 901-906.
35. MUKHERJEE, J.J. et al. 1997. Pheochromocytoma: effect of nonionic contrast medium in CT on circulating catecholamine levels. Radiology 202: 227-231.
36. DINER, E.K. et al. 2005. Partial adrenalectomy: The National Cancer Institute experience. Urology 66: 19-23.
37. GUERRIERI, M. et al. 2005. Laparoscopic adrenalectomy in pheochromocytomas. J. Endocrinol. Invest. 28: 523-527.
38. DAVIES, M.J. et al. 2004. A comparison of open and laparoscopic approaches to adrenalectomy in patients with phaeochromocytoma. Anaesth. Intensive Care 32: 224-229.
39. ELDADAH, B.A. et al. 2004. Cardiac uptake-1 inhibition by high circulating norepinephrine levels in patients with pheochromocytoma. Hypertension 43: 1227-1234.
40. AVERBUCH, S.D. et al. 1988. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann. Intern. Med. 109: 267-273.
41. PATEL, S.R. et al. 1995. A 15-year experience with chemotherapy of patients with paraganglioma. Cancer 76: 1476-1480.
42. KOSHIHARA, K. et al. 1989. Remarkable regression of malignant paraganglioma in the retroperitoneum and neck after chemotherapy: report of a case and a review of the literature. Jpn. J. Med. 28: 772-776.
43. MICHAELSON, M.D. & M.R. SMITH. 2005. Bisphosphonates for treatment and prevention of bone metastases. J. Clin. Oncol. 23: 8219-8224.
44. BRIEGER, J. et al. 2005. Vascular endothelial growth factor expression, vascularization and proliferation in paragangliomas. ORL J. Otorhinolaryngol. Relat. Spec. 67: 119-124.
45. TONG, A.L. et al. 2004. [Expression of transforming growth factor alpha, tumor necrosis factor alpha, and vascular endothelial growth factor of human pheochromocytoma tissues]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 26: 426-431.
46. TAKEKOSHI, K. et al. 2004. Expression of vascular endothelial growth factor (VEGF) and its cognate receptors in human pheochromocytomas. Life Sci. 74: 863-871.
47. SALMENKIVI, K. et al. 2003. VEGF in 105 pheochromocytomas: enhanced expression correlates with malignant outcome. APMIS. 11: 458-64.
48. GIMENEZ-ROQUEPLO, A.P. et al. 2002. Functional consequences of a SDHB gene mutation in an apparently sporadic pheochromocytoma. J. Clin. Endocrinol. Metab. 87: 4771-4774.
49. MIDDEKE, M. et al. 2002. In vitro and in vivo angiogenesis in PC12 pheochromocytoma cells is mediated by vascular endothelial growth factor. Exp. Clin. Endocrinol. Diabetes 110: 386-392.
50. ZIELKE, A. et al. 2002. VEGF-mediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors. Surgery 132: 1056-1063.
51. FERRARA, N. et al. 2004. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discovery 3: 391-400.
52. ZACHARIAH, A. & G. SCOFF. 2005. Update on angiogenesis inhibitors. Curr. Opin. Oncol. 17: 578-583.
53. RYAN, A.J. & S.R. WEDGE. 2005. ZD6474-a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br. J. Cancer 92: S6-13.
54. HOLDEN, S.N. et al. 2005. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann. Oncol. 16: 1391-1397.
55. ZATELLI, M.C. et al. 2005. Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism. J. Clin. Endocrinol. Metab. 90: 5754-5760.
56. STARIKOVA, A.M. et al. 1998. Nifedipine-induced morphological differentiation of rat pheochromocytoma cells. Neuroscience 86: 611-617.
57. YU, L. et al. 1996. Radiation therapy of metastatic pheochromocytoma: case report and review of the literature. Am. J. Clin. Oncol. 19: 389-393.
58. GERSZTEN, P.C. & W.C. WELCH. 2004. Cyberknife radiosurgery for metastatic spine tumors. Neurosurg. Clin. N. Am. 15: 491-501.
59. SISSON, J.C. et al. 1984. Radiopharmaceutical treatment of malignant pheochromocytoma. J. Nucl. Med. 24: 197-206.
60. CHARBONNEL, B. et al. 1988. Le traitement des pheochromocytomas malins par la 131-I-metaiodobenzylguanidine. Ann. Endocrinol. (Paris) 49: 344-347.
61. BRENDEL, A. et al. 1989. Radionuclide therapy of pheochromocytomas and neuroblastomas using Iodine-131-metaiodobenzylguanidine (MIGB). Clin. Nucl. Med. 14: 19-21.
62. TRONCOME, L. et al. 1990. The diagnostic and therapeutic utility of radioidonated metaiodobenzylguanidine (MIBG): 5 years experience. Europ. J. Nucl. Med. 16: 325-335.
63. 131I-MIBG): a comprehensive review of 116 reported patients. J. Endocrinol. Invest. 20: 648-658.
64. 131I-mIBG). Clin. Endocrinol. 55: 47-60.
65. SAFFORD, S.D. et al. 2003. Iodine-131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery 134: 956-063.
66. KORAL, K.F. et al. 1989. Calculating radiation absorbed dose for pheochromocytoma tumors in 131-I MIBG therapy. Int. J. Radiat. Oncol. Bio. Phys. 17: 211-218.
67. 131I-metaiodobenzylguanidine: implications for targeted radiotherapy of neuroblastoma. Eur. J. Cancer 31: 576-581.
68. 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J. Clin. Oncol. 16: 229-236.
69. SUNG, K.W. et al. 2002. Double high-dose chemotherapy with autologous stem cell transplantation in patients with high-risk neuroblastoma: a pilot study in a single center. J. Kor. Med. Sci. 17: 537-543.
70. CHOU, T. et al. 2005. Isolation and transplantation of highly purified autologous peripheral CD34+progenitor cells: purging efficacy, hematopoietic reconstitution following high dose chemotherapy in patients with breast cancer: results of a feasibility study in Japan. Breast Cancer 12: 178-188.
71. 131I-Metaiodobenzylguanadine therapy for 12 patients with malignant pheochromocytoma. Cancer 98: 1-10.
72. BENNETT, J.M. & R.S. KOMROKJI. 2005. The myelodysplastic syndromes: diagnosis, molecular biology and risk assessment. Hematology 10: 258-269.
73. 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma. J. Pediatr. Hematol. Oncol. 25: 543-547.
74. 131I- metaiodobenzylguanidine. Cancer 97: 1332-1338.